Tuesday, July 09, 2019 9:13:31 AM
JELIS enrolled all of its subjects in the late 1990's (suboptimal SOC compared with today), 70% were women, and all were initially placed on very low dose statins (i.e. 5 mg/d simvastatin). 27% discontinued statin use during the study. It was also open label, with the only significant individual endpoint affected being unstable angina. And if strokes were added to the primary composite endpoint (only then making the MCE endpoint comparable with REDUCE-IT), the study would have failed with an 11.5% RRR. Strokes actually trended worse for EPA group in JELIS.
If you are hanging your hat on JELIS, and thus recommended 2 g/d, and you think REDUCE-IT results were barely at all confounded (so that nearly all of the 28% risk reduction in strokes is accurate, etc.), then you are harming those you advise, because 4 g/d may reduce strokes appreciably while 2 g/d evidently does not (per JELIS). One could carry that logic forward with other endpoints as well, as none of the individual components of the composite MCE endpoint in JELIS were significantly reduced except angina.
What would be far better advice that allows a patient to get high EPA blood serum levels (the entire goal of taking Vascepa) while also being able to actually afford the benefit? Answer: Purchasing OTC high-EPA products with third party CoAs, showing exceptional purity and accuracy of labeled quantity of EPA per dose. Also, choosing an ethyl ester EPA supplement (such as Vascepa) is subpar to other forms that have consistently shown to be better absorbed, especially when taken with a lower fat meal or with polypharmacy in evening before sleep (as many patients in a real-world setting do). For example, the very popular rTG form:
OmegaVia and Nordic Naturals exclusively produce this more modern form. In fact, these companies' products may very well be higher purity than Vascepa, as the USP-NF holds pharma companies to lower standards of TOTOX than IFOS and GOED; USP-NF allows peroxide value of up to 10 mEq/kg and p-anisidine of up to 25. Meanwhile, IFOS and GOED have these set at 5 and 20 respectively. OmegaVia (and Nordic Naturals) is well below IFOS threshold.
OmegaVia also conducts routine CoAs to ensure every batch is of very high quality:
OmegaVia is thus better absorbed than Vascepa when taken with or without food; is not dependent upon a high fat meal for absorption (as is Vascepa); and is subject to higher purity and toxicity standards than Vascepa.
Not to mention Vascepa, being a fatty acid ethyl ester, may lead to liver and other organ damage from long-term use:
https://www.jmmc-online.com/article/S0022-2828(98)90812-4/pdf
http://www.jbc.org/content/265/17/9688.full.pdf
Also see pages 55 - 66 in our citizen petition here:
http://www.jbc.org/content/265/17/9688.full.pdf
Re-esterified triglyceride forms are thus a far better choice on multiple fronts. And highly affordable:
And if one is worried about whether the dietary supplement sector can handle the demand, they seem to be doing just fine, even at the near peak of Lovaza sales:
So there you have it. Buy high EPA supplements with third-party CoAs. Probably higher purity than Vascepa, of better absorbed forms (rTG, etc.), and you can avoid ethyl ester forms that may over many years lead to organ damage. Then you can recommend the dose actually studied in REDUCE-IT, and not a dose contrived from a faulty interpretation of an older, irrelevant study (JELIS).
Regards,
-MRC Team
...
Recent AMRN News
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:31:04 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM